Understanding the 'honeymoon' period in type 1 diabetes
Multimodal analysis of the "honeymoon period" in autoimmune diabetes
Researchers are combining immune tests, metabolic measures, and patient information to find markers that predict how long the early 'honeymoon' period lasts in people newly diagnosed with type 1 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11323026 on NIH RePORTER |
What this research studies
As someone with new type 1 diabetes, this team will collect blood and metabolic data and combine immune tests, metabolic measures, and basic patient information to spot patterns during the early 'honeymoon' period. They will follow people over time after diagnosis to see who has a short or long partial remission and why. The researchers plan to build combined biomarker scores from immune and metabolic signals that predict how quickly insulin needs change. Those biomarker scores would be tested for usefulness in designing better clinical trials and targeting therapies.
Who could benefit from this research
Good fit: Ideal candidates are people recently diagnosed with type 1 diabetes—especially children and young adults within the first few months after starting insulin.
Not a fit: People with long-standing type 1 diabetes, those with type 2 diabetes, or anyone unwilling to give blood samples or travel to the study site are unlikely to benefit directly from participation.
Why it matters
Potential benefit: If successful, this work could help doctors predict honeymoon length, personalize monitoring and trial enrollment, and speed the development of better treatments for type 1 diabetes.
How similar studies have performed: Past natural-history studies have described the honeymoon phase and linked some immune or metabolic markers to outcomes, but creating validated composite biomarkers for prediction is relatively new and not yet proven.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Davidson, Howard W — University of Colorado Denver
- Study coordinator: Davidson, Howard W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.